Sugi Predict

Sugi Predict / Compounds / SCHEMBL9980415

SCHEMBL9980415

SCHEMBL9980415

N#Cc1n[nH]c2cc(Cl)ccc12

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAP2K4 P45985 3/20 0.44
▸ PSMB8 P28062 1/20 0.44
▸ TRPA1 O75762 2/20 0.43
▸ GSK3B P49841 2/20 0.41
▸ ERBB2 P04626 1/20 0.41
▸ SGK1 O00141 1/20 0.39
▸ DAO P14920 1/20 0.38
▸ NOS1 P29475 1/20 0.38
▸ DYRK1A Q13627 1/20 0.38
▸ USP8 P40818 2/20 0.37
▸ USP7 Q93009 2/20 0.37
▸ USP47 Q96K76 1/20 0.37
▸ CHEK1 O14757 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ PARP1 P09874 1/20 0.36
▸ GPR84 Q9NQS5 1/20 0.36
▸ FADS1 O60427 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31621168 1.00 MAP2K4 (0.44) MAP2K4PSMB8TRPA1GSK3BERBB2
SCHEMBL15540801 0.86 FADS1 (0.45) PSMB8ERBB2NOS1DYRK1AUSP8
SCHEMBL5637837 0.82 MAP2K4 (0.44) MAP2K4TRPA1GSK3BDAONOS1
SCHEMBL16252839 0.79 MAP2K4 (0.51) MAP2K4ERBB2
SCHEMBL29937465 0.79 ITK (0.51) MAP2K4ERBB2USP8USP7
SCHEMBL11977413 0.79 PDPK1 (0.58) GSK3BERBB2NOS1DYRK1A
SCHEMBL15942805 0.79 ITK (0.51) MAP2K4ERBB2USP8USP7
SCHEMBL30224844 0.79 PDPK1 (0.58) GSK3BERBB2NOS1DYRK1A
SCHEMBL3593032 0.75 MAP2K4 (0.50) MAP2K4TRPA1GSK3BDAONOS1
SCHEMBL14738828 0.75 MAP2K4 (0.63) MAP2K4TRPA1GSK3BDAONOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435080-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2025-10-07 — — US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 — — US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 — — US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 — — US disclosed
CN-108738320-B cGMP modulators for the treatment of cardiovascular diseases 默沙东公司 2021-11-19 — — CN disclosed
EP-3394067-B1 4-AMINO-2-(1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL)-6-OXO-6,7-DIHYDRO-5H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THE RESPECTIVE (1H-INDAZOL-3-YL) DERIVATIVES AS CGMP MODULATORS FOR TREATING CARDIOVASCULAR DISEASES MERCK SHARP & DOHME (US) 2020-04-01 — — EP disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 — — US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 — — US disclosed
US-10428076-B2 Soluble guanylate cyclase stimulators MERCK SHARP & DOHME CORP. (US) 2019-10-01 — — US disclosed
EP-3538520-A2 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2019-09-18 — — EP disclosed
WO-2017112617-A1 4-AMINO-2-(1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL)-6-OXO-6,7-DIHYDRO-5H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THE RESPECTIVE (1H-INDAZOL-3-YL) DERIVATIVES AS CGMP MODULATORS FOR TREATING CARDIOVASCULAR DISEASES MERCK SHARP & DOHME CORP. (US) 2017-06-29 — — WO disclosed
WO-2017107052-A1 SOLUBLE GUANYLATE CYCLASE STIMULATORS MERCK SHARP & DOHME CORP. (US) 2017-06-29 — — WO disclosed
US-20170174693-A1 SOLUBLE GUANYLATE CYCLASE STIMULATORS MERCK SHARP & DOHME LLC 2017-06-22 — — US disclosed
US-9365574-B2 Soluble guanylate cyclase activators MERCK SHARP & DOHME CORP. (US) 2016-06-14 — — US disclosed
EP-2575473-B1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK SHARP & DOHME (US) 2016-01-20 — — EP disclosed
US-9023849-B2 Substituted fused imidazoles and pyrazoles and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-05-05 — — US disclosed
US-20130210824-A1 Substituted fused imidazoles and pyrazoles and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-08-15 — — US disclosed
EP-2575473-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS Merck Sharp & Dohme Corp. (US) 2013-04-10 — — EP disclosed
US-20130072492-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK SHARP & DOHME LLC 2013-03-21 — — US disclosed
WO-2011149921-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK SHARP & DOHME CORP. (US) 2011-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071318-A1 SGC STIMULATORS GUCY1A2, GMPS, PDE2A MAP2K4 3582/4885PSMB8 4372/4885TRPA1 2500/4885
US-20220017515-A1 sGC STIMULATORS GUCY1A2, PRKG1, PDE2A MAP2K4 3399/4885PSMB8 4340/4885TRPA1 2542/4885
US-20130072492-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS GUCY1A2, GUCY1A1, PDE2A MAP2K4 3919/4885PSMB8 4352/4885TRPA1 1917/4885
US-20130210824-A1 Substituted fused imidazoles and pyrazoles and use thereof CYP4F3, CYP11B2, CYP4F2 MAP2K4 1174/4885PSMB8 3241/4885TRPA1 3646/4885
US-20170174693-A1 SOLUBLE GUANYLATE CYCLASE STIMULATORS GUCY1A1, GUCY1A2, PDE2A MAP2K4 4130/4885PSMB8 4682/4885TRPA1 1995/4885
US-12435080-B2 sGC stimulators GUCY1A2, PRKG1, PDE2A MAP2K4 3399/4885PSMB8 4340/4885TRPA1 2542/4885
US-10428076-B2 Soluble guanylate cyclase stimulators GUCY1A1, GUCY1A2, PDE2A MAP2K4 4130/4885PSMB8 4682/4885TRPA1 1995/4885
US-11180493-B2 SGC stimulators GUCY1A2, GMPS, PDE2A MAP2K4 3582/4885PSMB8 4372/4885TRPA1 2500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.